Pharma BD Deal Intelligence
GlaxoSmithKline plc / Genmab A/S (ofatumumab/HuMax-CD20)
2006 · Co-Development · $2.1B · Complete
Announcement Sentiment
75
Strongly positive
Anti-CD20 mAb (Arzerra); $102M upfront + $357M equity + up to $1.6B milestones; record biotech license deal at the time
Key facts
- Announced Dec 19, 2006
- Deal value $2.1B
- Deal type Co-Development
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals